IL6 and COVID-19: Moreover, a previous study of our group showed that high levels of IL6 (above 30 pg/ml) were associated with worse prognosis of COVID-19, and also with a better response to tocilizumab, thereby suggesting a role of IL6 levels in guiding treatment and predicting response to this therapeutic agent (8).